Image Source: Pixabay

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index have market capitalizations ranging from $87M to $542M and average $269M. They were UP 3.9%, on average, last week and are now only UP 9.4% YTD. They are ranked below in descending order as to their performances.

1. Mind Medicine (MNMD): UP 8.2% last week
   • is primarily focused on the use of LSD* and MNMA*. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • Short Interest: 9.4%
   • Read: MindMed Reports Second Quarter 2023 Financial Results and Business Highlights
2. Compass Pathways (CMPS): UP 4.0% last week
   • focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • Short Interest: 18.6%  - A high short interest signals that investors have become more bearish and may be getting ready to sell and, as such, that it may be time to liquidate a long position.
   • Read: COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
3. GH Research (GHRS): UP 3.8% last week
   • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
   • Short Interest: 10.5%
   • Read: GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
4. Atai (ATAI): No Change last week
   • focused on the use of ketamine*, DMT* and ibogaine*.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Short Interest: 3.1%
   • Read: atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
5. Seelos (SEEL): No Change last week
   • focused on the use of ketamine*. Go here for much more extensive information on Ketamine.
   • Short Interest: 4.4%
   • Read: Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
6. Incannex Healthcare (IXHL): DOWN 0.7% last week
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • Short Interest: NA
   • Read: Incannex preparing psilocybin therapy FDA IND application

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.

If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL) of 23 such stocks of which the majority have market capitalizations of less than $50M. It was UP 11.0% last week but remains DOWN 2.2% YTD.

More By This Author:

Canadian Cannabis LPs Up 20% Last Week - Here's Why
Cannabis MSO Stocks Jumped 40% Last Week - Here's Why
Bubble In AI "Penny" Stocks Pricked In August